nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—CYP19A1—uterine cancer	0.514	1	CbGaD
Mefloquine—ABCB1—Progesterone—uterine cancer	0.033	0.175	CbGbCtD
Mefloquine—CYP2D6—Progesterone—uterine cancer	0.0311	0.164	CbGbCtD
Mefloquine—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0299	0.158	CbGbCtD
Mefloquine—ABCB1—Dactinomycin—uterine cancer	0.0262	0.138	CbGbCtD
Mefloquine—CYP3A4—Progesterone—uterine cancer	0.0198	0.105	CbGbCtD
Mefloquine—ABCB1—Etoposide—uterine cancer	0.0148	0.0781	CbGbCtD
Mefloquine—HBA2—oviduct—uterine cancer	0.0128	0.141	CbGeAlD
Mefloquine—CYP19A1—corpus luteum—uterine cancer	0.0114	0.125	CbGeAlD
Mefloquine—ABCB1—Doxorubicin—uterine cancer	0.0101	0.0533	CbGbCtD
Mefloquine—CYP2D6—Doxorubicin—uterine cancer	0.00949	0.0502	CbGbCtD
Mefloquine—CYP3A4—Etoposide—uterine cancer	0.00885	0.0468	CbGbCtD
Mefloquine—HBA2—artery—uterine cancer	0.00849	0.0937	CbGeAlD
Mefloquine—HBA2—exocrine gland—uterine cancer	0.0074	0.0817	CbGeAlD
Mefloquine—CYP3A4—Doxorubicin—uterine cancer	0.00604	0.0319	CbGbCtD
Mefloquine—CYP19A1—semen—uterine cancer	0.00533	0.0588	CbGeAlD
Mefloquine—HBA1—renal system—uterine cancer	0.00325	0.0359	CbGeAlD
Mefloquine—HBA2—epithelium—uterine cancer	0.00322	0.0355	CbGeAlD
Mefloquine—HBA2—smooth muscle tissue—uterine cancer	0.0031	0.0342	CbGeAlD
Mefloquine—HBA2—renal system—uterine cancer	0.00299	0.033	CbGeAlD
Mefloquine—HBA1—female reproductive system—uterine cancer	0.0026	0.0287	CbGeAlD
Mefloquine—HBA2—female reproductive system—uterine cancer	0.00239	0.0264	CbGeAlD
Mefloquine—HBA1—female gonad—uterine cancer	0.00237	0.0262	CbGeAlD
Mefloquine—HBA2—female gonad—uterine cancer	0.00218	0.024	CbGeAlD
Mefloquine—HBA1—lymph node—uterine cancer	0.00152	0.0168	CbGeAlD
Mefloquine—HBA2—lymph node—uterine cancer	0.0014	0.0154	CbGeAlD
Mefloquine—ADORA1—renal system—uterine cancer	0.00134	0.0148	CbGeAlD
Mefloquine—ADORA2A—female reproductive system—uterine cancer	0.00124	0.0137	CbGeAlD
Mefloquine—ADORA1—female reproductive system—uterine cancer	0.00107	0.0119	CbGeAlD
Mefloquine—ADORA1—vagina—uterine cancer	0.000972	0.0107	CbGeAlD
Mefloquine—BCHE—myometrium—uterine cancer	0.0009	0.00994	CbGeAlD
Mefloquine—CYP19A1—endometrium—uterine cancer	0.00088	0.00971	CbGeAlD
Mefloquine—CYP19A1—uterus—uterine cancer	0.000811	0.00895	CbGeAlD
Mefloquine—CYP19A1—female reproductive system—uterine cancer	0.000729	0.00804	CbGeAlD
Mefloquine—BCHE—uterine cervix—uterine cancer	0.000701	0.00773	CbGeAlD
Mefloquine—BCHE—smooth muscle tissue—uterine cancer	0.000681	0.00752	CbGeAlD
Mefloquine—CYP19A1—female gonad—uterine cancer	0.000663	0.00732	CbGeAlD
Mefloquine—BCHE—endometrium—uterine cancer	0.000634	0.00699	CbGeAlD
Mefloquine—ADORA1—lymph node—uterine cancer	0.000629	0.00694	CbGeAlD
Mefloquine—ACHE—lymph node—uterine cancer	0.000625	0.0069	CbGeAlD
Mefloquine—BCHE—mammalian vulva—uterine cancer	0.000613	0.00677	CbGeAlD
Mefloquine—BCHE—uterus—uterine cancer	0.000584	0.00645	CbGeAlD
Mefloquine—BCHE—female reproductive system—uterine cancer	0.000525	0.00579	CbGeAlD
Mefloquine—BCHE—vagina—uterine cancer	0.000475	0.00524	CbGeAlD
Mefloquine—CYP3A4—renal system—uterine cancer	0.000441	0.00487	CbGeAlD
Mefloquine—CYP2D6—renal system—uterine cancer	0.000434	0.00479	CbGeAlD
Mefloquine—ABCB1—myometrium—uterine cancer	0.000429	0.00474	CbGeAlD
Mefloquine—CYP19A1—lymph node—uterine cancer	0.000426	0.00471	CbGeAlD
Mefloquine—CYP3A4—female reproductive system—uterine cancer	0.000353	0.0039	CbGeAlD
Mefloquine—CYP2D6—female reproductive system—uterine cancer	0.000348	0.00384	CbGeAlD
Mefloquine—ABCB1—epithelium—uterine cancer	0.000337	0.00372	CbGeAlD
Mefloquine—ABCB1—uterine cervix—uterine cancer	0.000334	0.00369	CbGeAlD
Mefloquine—ABCB1—decidua—uterine cancer	0.000318	0.00351	CbGeAlD
Mefloquine—CYP2D6—female gonad—uterine cancer	0.000316	0.00349	CbGeAlD
Mefloquine—ABCB1—renal system—uterine cancer	0.000312	0.00345	CbGeAlD
Mefloquine—BCHE—lymph node—uterine cancer	0.000307	0.00339	CbGeAlD
Mefloquine—ABCB1—endometrium—uterine cancer	0.000302	0.00333	CbGeAlD
Mefloquine—ABCB1—mammalian vulva—uterine cancer	0.000292	0.00322	CbGeAlD
Mefloquine—ABCB1—uterus—uterine cancer	0.000278	0.00307	CbGeAlD
Mefloquine—Coma—Epirubicin—uterine cancer	0.000256	0.00159	CcSEcCtD
Mefloquine—Discomfort—Dactinomycin—uterine cancer	0.000254	0.00157	CcSEcCtD
Mefloquine—Influenza like illness—Doxorubicin—uterine cancer	0.000252	0.00156	CcSEcCtD
Mefloquine—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000251	0.00155	CcSEcCtD
Mefloquine—ABCB1—female reproductive system—uterine cancer	0.00025	0.00276	CbGeAlD
Mefloquine—Asthenia—Progesterone—uterine cancer	0.00025	0.00155	CcSEcCtD
Mefloquine—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00025	0.00155	CcSEcCtD
Mefloquine—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00025	0.00155	CcSEcCtD
Mefloquine—Pruritus—Progesterone—uterine cancer	0.000246	0.00153	CcSEcCtD
Mefloquine—Oedema—Dactinomycin—uterine cancer	0.000246	0.00153	CcSEcCtD
Mefloquine—Aplastic anaemia—Doxorubicin—uterine cancer	0.000243	0.00151	CcSEcCtD
Mefloquine—Neuropathy—Doxorubicin—uterine cancer	0.000243	0.00151	CcSEcCtD
Mefloquine—Thrombocytopenia—Dactinomycin—uterine cancer	0.000241	0.00149	CcSEcCtD
Mefloquine—Diarrhoea—Progesterone—uterine cancer	0.000238	0.00148	CcSEcCtD
Mefloquine—Erythema multiforme—Etoposide—uterine cancer	0.000237	0.00147	CcSEcCtD
Mefloquine—Coma—Doxorubicin—uterine cancer	0.000237	0.00147	CcSEcCtD
Mefloquine—Eye disorder—Etoposide—uterine cancer	0.000234	0.00145	CcSEcCtD
Mefloquine—Flushing—Etoposide—uterine cancer	0.000233	0.00144	CcSEcCtD
Mefloquine—Cardiac disorder—Etoposide—uterine cancer	0.000233	0.00144	CcSEcCtD
Mefloquine—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000233	0.00144	CcSEcCtD
Mefloquine—Dizziness—Progesterone—uterine cancer	0.00023	0.00143	CcSEcCtD
Mefloquine—ABCB1—female gonad—uterine cancer	0.000228	0.00251	CbGeAlD
Mefloquine—Angiopathy—Etoposide—uterine cancer	0.000228	0.00141	CcSEcCtD
Mefloquine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000226	0.0014	CcSEcCtD
Mefloquine—ABCB1—vagina—uterine cancer	0.000226	0.0025	CbGeAlD
Mefloquine—Hepatic failure—Epirubicin—uterine cancer	0.000226	0.0014	CcSEcCtD
Mefloquine—Mediastinal disorder—Etoposide—uterine cancer	0.000226	0.0014	CcSEcCtD
Mefloquine—Chills—Etoposide—uterine cancer	0.000225	0.00139	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000224	0.00139	CcSEcCtD
Mefloquine—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000223	0.00138	CcSEcCtD
Mefloquine—Alopecia—Etoposide—uterine cancer	0.000222	0.00137	CcSEcCtD
Mefloquine—Vomiting—Progesterone—uterine cancer	0.000221	0.00137	CcSEcCtD
Mefloquine—Rash—Progesterone—uterine cancer	0.00022	0.00136	CcSEcCtD
Mefloquine—Dermatitis—Progesterone—uterine cancer	0.000219	0.00136	CcSEcCtD
Mefloquine—Headache—Progesterone—uterine cancer	0.000218	0.00135	CcSEcCtD
Mefloquine—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000216	0.00134	CcSEcCtD
Mefloquine—Decreased appetite—Dactinomycin—uterine cancer	0.000214	0.00133	CcSEcCtD
Mefloquine—Dermatitis bullous—Epirubicin—uterine cancer	0.000213	0.00132	CcSEcCtD
Mefloquine—Fatigue—Dactinomycin—uterine cancer	0.000212	0.00132	CcSEcCtD
Mefloquine—Muscle spasms—Etoposide—uterine cancer	0.00021	0.0013	CcSEcCtD
Mefloquine—Hepatic failure—Doxorubicin—uterine cancer	0.000209	0.0013	CcSEcCtD
Mefloquine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000209	0.00129	CcSEcCtD
Mefloquine—Nausea—Progesterone—uterine cancer	0.000207	0.00128	CcSEcCtD
Mefloquine—Feeling abnormal—Dactinomycin—uterine cancer	0.000203	0.00126	CcSEcCtD
Mefloquine—Ill-defined disorder—Etoposide—uterine cancer	0.000203	0.00126	CcSEcCtD
Mefloquine—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000201	0.00125	CcSEcCtD
Mefloquine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000201	0.00124	CcSEcCtD
Mefloquine—Affect lability—Epirubicin—uterine cancer	0.0002	0.00124	CcSEcCtD
Mefloquine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000199	0.00123	CcSEcCtD
Mefloquine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000199	0.00123	CcSEcCtD
Mefloquine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000198	0.00123	CcSEcCtD
Mefloquine—Malaise—Etoposide—uterine cancer	0.000197	0.00122	CcSEcCtD
Mefloquine—Dermatitis bullous—Doxorubicin—uterine cancer	0.000197	0.00122	CcSEcCtD
Mefloquine—Vertigo—Etoposide—uterine cancer	0.000196	0.00122	CcSEcCtD
Mefloquine—Leukopenia—Etoposide—uterine cancer	0.000195	0.00121	CcSEcCtD
Mefloquine—Body temperature increased—Dactinomycin—uterine cancer	0.000195	0.00121	CcSEcCtD
Mefloquine—Abdominal pain—Dactinomycin—uterine cancer	0.000195	0.00121	CcSEcCtD
Mefloquine—Mood swings—Epirubicin—uterine cancer	0.000193	0.00119	CcSEcCtD
Mefloquine—Loss of consciousness—Etoposide—uterine cancer	0.000192	0.00119	CcSEcCtD
Mefloquine—Ataxia—Epirubicin—uterine cancer	0.000191	0.00118	CcSEcCtD
Mefloquine—Convulsion—Etoposide—uterine cancer	0.000189	0.00117	CcSEcCtD
Mefloquine—Hypertension—Etoposide—uterine cancer	0.000188	0.00117	CcSEcCtD
Mefloquine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000187	0.00116	CcSEcCtD
Mefloquine—Chest pain—Etoposide—uterine cancer	0.000186	0.00115	CcSEcCtD
Mefloquine—Affect lability—Doxorubicin—uterine cancer	0.000185	0.00115	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000185	0.00114	CcSEcCtD
Mefloquine—Discomfort—Etoposide—uterine cancer	0.000184	0.00114	CcSEcCtD
Mefloquine—Hypersensitivity—Dactinomycin—uterine cancer	0.000181	0.00112	CcSEcCtD
Mefloquine—Confusional state—Etoposide—uterine cancer	0.00018	0.00111	CcSEcCtD
Mefloquine—Muscular weakness—Epirubicin—uterine cancer	0.000179	0.00111	CcSEcCtD
Mefloquine—Anaphylactic shock—Etoposide—uterine cancer	0.000178	0.0011	CcSEcCtD
Mefloquine—Mood swings—Doxorubicin—uterine cancer	0.000178	0.0011	CcSEcCtD
Mefloquine—Ataxia—Doxorubicin—uterine cancer	0.000177	0.0011	CcSEcCtD
Mefloquine—Asthenia—Dactinomycin—uterine cancer	0.000177	0.00109	CcSEcCtD
Mefloquine—Thrombocytopenia—Etoposide—uterine cancer	0.000174	0.00108	CcSEcCtD
Mefloquine—Tachycardia—Etoposide—uterine cancer	0.000174	0.00108	CcSEcCtD
Mefloquine—Skin disorder—Etoposide—uterine cancer	0.000173	0.00107	CcSEcCtD
Mefloquine—Hyperhidrosis—Etoposide—uterine cancer	0.000172	0.00107	CcSEcCtD
Mefloquine—Diarrhoea—Dactinomycin—uterine cancer	0.000168	0.00104	CcSEcCtD
Mefloquine—Hypotension—Etoposide—uterine cancer	0.000166	0.00103	CcSEcCtD
Mefloquine—Muscular weakness—Doxorubicin—uterine cancer	0.000166	0.00103	CcSEcCtD
Mefloquine—Paraesthesia—Etoposide—uterine cancer	0.00016	0.000991	CcSEcCtD
Mefloquine—Dyspnoea—Etoposide—uterine cancer	0.000159	0.000984	CcSEcCtD
Mefloquine—Somnolence—Etoposide—uterine cancer	0.000158	0.000982	CcSEcCtD
Mefloquine—Pneumonia—Epirubicin—uterine cancer	0.000158	0.000976	CcSEcCtD
Mefloquine—Vomiting—Dactinomycin—uterine cancer	0.000157	0.00097	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000155	0.000962	CcSEcCtD
Mefloquine—Rash—Dactinomycin—uterine cancer	0.000155	0.000962	CcSEcCtD
Mefloquine—Decreased appetite—Etoposide—uterine cancer	0.000155	0.00096	CcSEcCtD
Mefloquine—Renal failure—Epirubicin—uterine cancer	0.000154	0.000954	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000154	0.000953	CcSEcCtD
Mefloquine—Fatigue—Etoposide—uterine cancer	0.000154	0.000952	CcSEcCtD
Mefloquine—Neuropathy peripheral—Epirubicin—uterine cancer	0.000154	0.000951	CcSEcCtD
Mefloquine—Sweating—Epirubicin—uterine cancer	0.00015	0.00093	CcSEcCtD
Mefloquine—Hepatobiliary disease—Epirubicin—uterine cancer	0.000148	0.000918	CcSEcCtD
Mefloquine—Feeling abnormal—Etoposide—uterine cancer	0.000147	0.00091	CcSEcCtD
Mefloquine—ABCB1—lymph node—uterine cancer	0.000146	0.00162	CbGeAlD
Mefloquine—Nausea—Dactinomycin—uterine cancer	0.000146	0.000906	CcSEcCtD
Mefloquine—Agranulocytosis—Epirubicin—uterine cancer	0.000146	0.000906	CcSEcCtD
Mefloquine—Pneumonia—Doxorubicin—uterine cancer	0.000146	0.000903	CcSEcCtD
Mefloquine—Gastrointestinal pain—Etoposide—uterine cancer	0.000146	0.000903	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000144	0.00089	CcSEcCtD
Mefloquine—Bradycardia—Epirubicin—uterine cancer	0.000143	0.000887	CcSEcCtD
Mefloquine—Renal failure—Doxorubicin—uterine cancer	0.000142	0.000883	CcSEcCtD
Mefloquine—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000142	0.00088	CcSEcCtD
Mefloquine—Urticaria—Etoposide—uterine cancer	0.000142	0.000877	CcSEcCtD
Mefloquine—Body temperature increased—Etoposide—uterine cancer	0.000141	0.000873	CcSEcCtD
Mefloquine—Abdominal pain—Etoposide—uterine cancer	0.000141	0.000873	CcSEcCtD
Mefloquine—Sweating—Doxorubicin—uterine cancer	0.000139	0.000861	CcSEcCtD
Mefloquine—Connective tissue disorder—Epirubicin—uterine cancer	0.000138	0.000856	CcSEcCtD
Mefloquine—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000137	0.000849	CcSEcCtD
Mefloquine—Visual impairment—Epirubicin—uterine cancer	0.000135	0.000839	CcSEcCtD
Mefloquine—Agranulocytosis—Doxorubicin—uterine cancer	0.000135	0.000838	CcSEcCtD
Mefloquine—Erythema multiforme—Epirubicin—uterine cancer	0.000133	0.000824	CcSEcCtD
Mefloquine—Bradycardia—Doxorubicin—uterine cancer	0.000132	0.000821	CcSEcCtD
Mefloquine—Eye disorder—Epirubicin—uterine cancer	0.000131	0.000814	CcSEcCtD
Mefloquine—Hypersensitivity—Etoposide—uterine cancer	0.000131	0.000813	CcSEcCtD
Mefloquine—Tinnitus—Epirubicin—uterine cancer	0.000131	0.000812	CcSEcCtD
Mefloquine—Flushing—Epirubicin—uterine cancer	0.00013	0.000808	CcSEcCtD
Mefloquine—Cardiac disorder—Epirubicin—uterine cancer	0.00013	0.000808	CcSEcCtD
Mefloquine—Asthenia—Etoposide—uterine cancer	0.000128	0.000792	CcSEcCtD
Mefloquine—Connective tissue disorder—Doxorubicin—uterine cancer	0.000128	0.000792	CcSEcCtD
Mefloquine—Angiopathy—Epirubicin—uterine cancer	0.000128	0.00079	CcSEcCtD
Mefloquine—Mediastinal disorder—Epirubicin—uterine cancer	0.000127	0.000785	CcSEcCtD
Mefloquine—Chills—Epirubicin—uterine cancer	0.000126	0.000782	CcSEcCtD
Mefloquine—Pruritus—Etoposide—uterine cancer	0.000126	0.000781	CcSEcCtD
Mefloquine—Visual impairment—Doxorubicin—uterine cancer	0.000125	0.000777	CcSEcCtD
Mefloquine—Alopecia—Epirubicin—uterine cancer	0.000124	0.00077	CcSEcCtD
Mefloquine—Mental disorder—Epirubicin—uterine cancer	0.000123	0.000763	CcSEcCtD
Mefloquine—Erythema multiforme—Doxorubicin—uterine cancer	0.000123	0.000762	CcSEcCtD
Mefloquine—Erythema—Epirubicin—uterine cancer	0.000122	0.000758	CcSEcCtD
Mefloquine—Malnutrition—Epirubicin—uterine cancer	0.000122	0.000758	CcSEcCtD
Mefloquine—Diarrhoea—Etoposide—uterine cancer	0.000122	0.000755	CcSEcCtD
Mefloquine—Eye disorder—Doxorubicin—uterine cancer	0.000122	0.000753	CcSEcCtD
Mefloquine—Tinnitus—Doxorubicin—uterine cancer	0.000121	0.000751	CcSEcCtD
Mefloquine—Cardiac disorder—Doxorubicin—uterine cancer	0.000121	0.000748	CcSEcCtD
Mefloquine—Flushing—Doxorubicin—uterine cancer	0.000121	0.000748	CcSEcCtD
Mefloquine—Angiopathy—Doxorubicin—uterine cancer	0.000118	0.000731	CcSEcCtD
Mefloquine—Dizziness—Etoposide—uterine cancer	0.000118	0.00073	CcSEcCtD
Mefloquine—Muscle spasms—Epirubicin—uterine cancer	0.000118	0.000729	CcSEcCtD
Mefloquine—Mediastinal disorder—Doxorubicin—uterine cancer	0.000117	0.000726	CcSEcCtD
Mefloquine—Chills—Doxorubicin—uterine cancer	0.000117	0.000723	CcSEcCtD
Mefloquine—Vision blurred—Epirubicin—uterine cancer	0.000115	0.000715	CcSEcCtD
Mefloquine—Alopecia—Doxorubicin—uterine cancer	0.000115	0.000712	CcSEcCtD
Mefloquine—Mental disorder—Doxorubicin—uterine cancer	0.000114	0.000706	CcSEcCtD
Mefloquine—Ill-defined disorder—Epirubicin—uterine cancer	0.000114	0.000704	CcSEcCtD
Mefloquine—Vomiting—Etoposide—uterine cancer	0.000113	0.000702	CcSEcCtD
Mefloquine—Erythema—Doxorubicin—uterine cancer	0.000113	0.000702	CcSEcCtD
Mefloquine—Malnutrition—Doxorubicin—uterine cancer	0.000113	0.000702	CcSEcCtD
Mefloquine—Agitation—Epirubicin—uterine cancer	0.000112	0.000697	CcSEcCtD
Mefloquine—Rash—Etoposide—uterine cancer	0.000112	0.000696	CcSEcCtD
Mefloquine—Dermatitis—Etoposide—uterine cancer	0.000112	0.000695	CcSEcCtD
Mefloquine—Headache—Etoposide—uterine cancer	0.000112	0.000692	CcSEcCtD
Mefloquine—Malaise—Epirubicin—uterine cancer	0.00011	0.000684	CcSEcCtD
Mefloquine—Vertigo—Epirubicin—uterine cancer	0.00011	0.000681	CcSEcCtD
Mefloquine—Syncope—Epirubicin—uterine cancer	0.00011	0.00068	CcSEcCtD
Mefloquine—Leukopenia—Epirubicin—uterine cancer	0.00011	0.000679	CcSEcCtD
Mefloquine—Muscle spasms—Doxorubicin—uterine cancer	0.000109	0.000675	CcSEcCtD
Mefloquine—Palpitations—Epirubicin—uterine cancer	0.000108	0.00067	CcSEcCtD
Mefloquine—Loss of consciousness—Epirubicin—uterine cancer	0.000108	0.000666	CcSEcCtD
Mefloquine—Vision blurred—Doxorubicin—uterine cancer	0.000107	0.000661	CcSEcCtD
Mefloquine—Convulsion—Epirubicin—uterine cancer	0.000106	0.000657	CcSEcCtD
Mefloquine—Nausea—Etoposide—uterine cancer	0.000106	0.000656	CcSEcCtD
Mefloquine—Hypertension—Epirubicin—uterine cancer	0.000106	0.000655	CcSEcCtD
Mefloquine—Ill-defined disorder—Doxorubicin—uterine cancer	0.000105	0.000651	CcSEcCtD
Mefloquine—Arthralgia—Epirubicin—uterine cancer	0.000104	0.000646	CcSEcCtD
Mefloquine—Myalgia—Epirubicin—uterine cancer	0.000104	0.000646	CcSEcCtD
Mefloquine—Chest pain—Epirubicin—uterine cancer	0.000104	0.000646	CcSEcCtD
Mefloquine—Agitation—Doxorubicin—uterine cancer	0.000104	0.000645	CcSEcCtD
Mefloquine—Anxiety—Epirubicin—uterine cancer	0.000104	0.000643	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000103	0.000641	CcSEcCtD
Mefloquine—Discomfort—Epirubicin—uterine cancer	0.000103	0.000638	CcSEcCtD
Mefloquine—Malaise—Doxorubicin—uterine cancer	0.000102	0.000633	CcSEcCtD
Mefloquine—Vertigo—Doxorubicin—uterine cancer	0.000102	0.00063	CcSEcCtD
Mefloquine—Syncope—Doxorubicin—uterine cancer	0.000102	0.000629	CcSEcCtD
Mefloquine—Leukopenia—Doxorubicin—uterine cancer	0.000101	0.000628	CcSEcCtD
Mefloquine—Confusional state—Epirubicin—uterine cancer	0.000101	0.000624	CcSEcCtD
Mefloquine—Palpitations—Doxorubicin—uterine cancer	0.0001	0.00062	CcSEcCtD
Mefloquine—Oedema—Epirubicin—uterine cancer	9.99e-05	0.000619	CcSEcCtD
Mefloquine—Anaphylactic shock—Epirubicin—uterine cancer	9.99e-05	0.000619	CcSEcCtD
Mefloquine—Loss of consciousness—Doxorubicin—uterine cancer	9.95e-05	0.000617	CcSEcCtD
Mefloquine—Shock—Epirubicin—uterine cancer	9.83e-05	0.000609	CcSEcCtD
Mefloquine—Convulsion—Doxorubicin—uterine cancer	9.81e-05	0.000608	CcSEcCtD
Mefloquine—Nervous system disorder—Epirubicin—uterine cancer	9.79e-05	0.000607	CcSEcCtD
Mefloquine—Thrombocytopenia—Epirubicin—uterine cancer	9.78e-05	0.000606	CcSEcCtD
Mefloquine—Hypertension—Doxorubicin—uterine cancer	9.78e-05	0.000606	CcSEcCtD
Mefloquine—Tachycardia—Epirubicin—uterine cancer	9.75e-05	0.000604	CcSEcCtD
Mefloquine—Skin disorder—Epirubicin—uterine cancer	9.7e-05	0.000601	CcSEcCtD
Mefloquine—Hyperhidrosis—Epirubicin—uterine cancer	9.66e-05	0.000598	CcSEcCtD
Mefloquine—Arthralgia—Doxorubicin—uterine cancer	9.64e-05	0.000597	CcSEcCtD
Mefloquine—Myalgia—Doxorubicin—uterine cancer	9.64e-05	0.000597	CcSEcCtD
Mefloquine—Chest pain—Doxorubicin—uterine cancer	9.64e-05	0.000597	CcSEcCtD
Mefloquine—Anxiety—Doxorubicin—uterine cancer	9.61e-05	0.000595	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	9.57e-05	0.000593	CcSEcCtD
Mefloquine—Discomfort—Doxorubicin—uterine cancer	9.52e-05	0.00059	CcSEcCtD
Mefloquine—Hypotension—Epirubicin—uterine cancer	9.33e-05	0.000578	CcSEcCtD
Mefloquine—Confusional state—Doxorubicin—uterine cancer	9.32e-05	0.000577	CcSEcCtD
Mefloquine—Anaphylactic shock—Doxorubicin—uterine cancer	9.24e-05	0.000573	CcSEcCtD
Mefloquine—Oedema—Doxorubicin—uterine cancer	9.24e-05	0.000573	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Epirubicin—uterine cancer	9.1e-05	0.000564	CcSEcCtD
Mefloquine—Shock—Doxorubicin—uterine cancer	9.09e-05	0.000563	CcSEcCtD
Mefloquine—Nervous system disorder—Doxorubicin—uterine cancer	9.06e-05	0.000562	CcSEcCtD
Mefloquine—Thrombocytopenia—Doxorubicin—uterine cancer	9.05e-05	0.000561	CcSEcCtD
Mefloquine—Insomnia—Epirubicin—uterine cancer	9.03e-05	0.00056	CcSEcCtD
Mefloquine—Tachycardia—Doxorubicin—uterine cancer	9.02e-05	0.000559	CcSEcCtD
Mefloquine—Skin disorder—Doxorubicin—uterine cancer	8.98e-05	0.000556	CcSEcCtD
Mefloquine—Paraesthesia—Epirubicin—uterine cancer	8.97e-05	0.000556	CcSEcCtD
Mefloquine—Hyperhidrosis—Doxorubicin—uterine cancer	8.93e-05	0.000554	CcSEcCtD
Mefloquine—Dyspnoea—Epirubicin—uterine cancer	8.9e-05	0.000552	CcSEcCtD
Mefloquine—Somnolence—Epirubicin—uterine cancer	8.88e-05	0.00055	CcSEcCtD
Mefloquine—Dyspepsia—Epirubicin—uterine cancer	8.79e-05	0.000545	CcSEcCtD
Mefloquine—Decreased appetite—Epirubicin—uterine cancer	8.68e-05	0.000538	CcSEcCtD
Mefloquine—Hypotension—Doxorubicin—uterine cancer	8.64e-05	0.000535	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Epirubicin—uterine cancer	8.62e-05	0.000534	CcSEcCtD
Mefloquine—Fatigue—Epirubicin—uterine cancer	8.61e-05	0.000534	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Doxorubicin—uterine cancer	8.42e-05	0.000522	CcSEcCtD
Mefloquine—Insomnia—Doxorubicin—uterine cancer	8.36e-05	0.000518	CcSEcCtD
Mefloquine—Paraesthesia—Doxorubicin—uterine cancer	8.3e-05	0.000514	CcSEcCtD
Mefloquine—Dyspnoea—Doxorubicin—uterine cancer	8.24e-05	0.000511	CcSEcCtD
Mefloquine—Feeling abnormal—Epirubicin—uterine cancer	8.23e-05	0.00051	CcSEcCtD
Mefloquine—Somnolence—Doxorubicin—uterine cancer	8.22e-05	0.000509	CcSEcCtD
Mefloquine—Gastrointestinal pain—Epirubicin—uterine cancer	8.17e-05	0.000506	CcSEcCtD
Mefloquine—Dyspepsia—Doxorubicin—uterine cancer	8.13e-05	0.000504	CcSEcCtD
Mefloquine—Decreased appetite—Doxorubicin—uterine cancer	8.03e-05	0.000498	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Doxorubicin—uterine cancer	7.98e-05	0.000494	CcSEcCtD
Mefloquine—Fatigue—Doxorubicin—uterine cancer	7.97e-05	0.000494	CcSEcCtD
Mefloquine—Urticaria—Epirubicin—uterine cancer	7.93e-05	0.000492	CcSEcCtD
Mefloquine—Abdominal pain—Epirubicin—uterine cancer	7.9e-05	0.000489	CcSEcCtD
Mefloquine—Body temperature increased—Epirubicin—uterine cancer	7.9e-05	0.000489	CcSEcCtD
Mefloquine—Feeling abnormal—Doxorubicin—uterine cancer	7.62e-05	0.000472	CcSEcCtD
Mefloquine—Gastrointestinal pain—Doxorubicin—uterine cancer	7.56e-05	0.000468	CcSEcCtD
Mefloquine—Hypersensitivity—Epirubicin—uterine cancer	7.36e-05	0.000456	CcSEcCtD
Mefloquine—Urticaria—Doxorubicin—uterine cancer	7.34e-05	0.000455	CcSEcCtD
Mefloquine—Abdominal pain—Doxorubicin—uterine cancer	7.31e-05	0.000453	CcSEcCtD
Mefloquine—Body temperature increased—Doxorubicin—uterine cancer	7.31e-05	0.000453	CcSEcCtD
Mefloquine—Asthenia—Epirubicin—uterine cancer	7.17e-05	0.000444	CcSEcCtD
Mefloquine—Pruritus—Epirubicin—uterine cancer	7.07e-05	0.000438	CcSEcCtD
Mefloquine—Diarrhoea—Epirubicin—uterine cancer	6.83e-05	0.000423	CcSEcCtD
Mefloquine—Hypersensitivity—Doxorubicin—uterine cancer	6.81e-05	0.000422	CcSEcCtD
Mefloquine—Asthenia—Doxorubicin—uterine cancer	6.63e-05	0.000411	CcSEcCtD
Mefloquine—Dizziness—Epirubicin—uterine cancer	6.6e-05	0.000409	CcSEcCtD
Mefloquine—Pruritus—Doxorubicin—uterine cancer	6.54e-05	0.000405	CcSEcCtD
Mefloquine—Vomiting—Epirubicin—uterine cancer	6.35e-05	0.000393	CcSEcCtD
Mefloquine—Diarrhoea—Doxorubicin—uterine cancer	6.32e-05	0.000392	CcSEcCtD
Mefloquine—Rash—Epirubicin—uterine cancer	6.3e-05	0.00039	CcSEcCtD
Mefloquine—Dermatitis—Epirubicin—uterine cancer	6.29e-05	0.00039	CcSEcCtD
Mefloquine—Headache—Epirubicin—uterine cancer	6.26e-05	0.000388	CcSEcCtD
Mefloquine—Dizziness—Doxorubicin—uterine cancer	6.11e-05	0.000379	CcSEcCtD
Mefloquine—Nausea—Epirubicin—uterine cancer	5.93e-05	0.000368	CcSEcCtD
Mefloquine—Vomiting—Doxorubicin—uterine cancer	5.88e-05	0.000364	CcSEcCtD
Mefloquine—Rash—Doxorubicin—uterine cancer	5.83e-05	0.000361	CcSEcCtD
Mefloquine—Dermatitis—Doxorubicin—uterine cancer	5.82e-05	0.000361	CcSEcCtD
Mefloquine—Headache—Doxorubicin—uterine cancer	5.79e-05	0.000359	CcSEcCtD
Mefloquine—Nausea—Doxorubicin—uterine cancer	5.49e-05	0.00034	CcSEcCtD
Mefloquine—ACHE—Metabolism—STAR—uterine cancer	4.82e-05	0.00107	CbGpPWpGaD
Mefloquine—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	4.8e-05	0.00106	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—AKR1C1—uterine cancer	4.8e-05	0.00106	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	4.78e-05	0.00106	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	4.77e-05	0.00105	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	4.76e-05	0.00105	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—FBXW7—uterine cancer	4.71e-05	0.00104	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—CDKN1B—uterine cancer	4.7e-05	0.00104	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—CXCL8—uterine cancer	4.68e-05	0.00103	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	4.63e-05	0.00102	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	4.55e-05	0.00101	CbGpPWpGaD
Mefloquine—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	4.52e-05	0.001	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RNF43—uterine cancer	4.5e-05	0.000995	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	4.48e-05	0.000991	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	4.47e-05	0.000989	CbGpPWpGaD
Mefloquine—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	4.46e-05	0.000987	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	4.45e-05	0.000985	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—AKR1B1—uterine cancer	4.43e-05	0.00098	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—STAR—uterine cancer	4.43e-05	0.00098	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—PTEN—uterine cancer	4.41e-05	0.000976	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—CXCL8—uterine cancer	4.41e-05	0.000976	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	4.39e-05	0.00097	CbGpPWpGaD
Mefloquine—ACHE—Phospholipid metabolism—PIK3CA—uterine cancer	4.36e-05	0.000965	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—PTEN—uterine cancer	4.32e-05	0.000956	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—uterine cancer	4.32e-05	0.000955	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—CCL2—uterine cancer	4.31e-05	0.000953	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	4.31e-05	0.000953	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—AKR1B1—uterine cancer	4.3e-05	0.000951	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—STAR—uterine cancer	4.3e-05	0.000951	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	4.25e-05	0.00094	CbGpPWpGaD
Mefloquine—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	4.21e-05	0.000932	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—EP300—uterine cancer	4.21e-05	0.000931	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—FBXW7—uterine cancer	4.2e-05	0.000929	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—INHBA—uterine cancer	4.11e-05	0.00091	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—PIK3CA—uterine cancer	4.11e-05	0.000909	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—KRAS—uterine cancer	4.06e-05	0.000898	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—uterine cancer	3.97e-05	0.000877	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—TP53—uterine cancer	3.91e-05	0.000865	CbGpPWpGaD
Mefloquine—BCHE—Phospholipid metabolism—PIK3CA—uterine cancer	3.89e-05	0.000861	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—NRAS—uterine cancer	3.86e-05	0.000853	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—VEGFA—uterine cancer	3.8e-05	0.00084	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—POLD1—uterine cancer	3.78e-05	0.000837	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—AKR1C1—uterine cancer	3.7e-05	0.000819	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—AKR1C3—uterine cancer	3.69e-05	0.000817	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—uterine cancer	3.67e-05	0.000811	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	3.66e-05	0.00081	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—TP53—uterine cancer	3.61e-05	0.000798	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PGR—uterine cancer	3.6e-05	0.000796	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—AKR1C1—uterine cancer	3.54e-05	0.000782	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—POLD1—uterine cancer	3.48e-05	0.000769	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—YWHAE—uterine cancer	3.43e-05	0.000759	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—CXCL8—uterine cancer	3.41e-05	0.000753	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—POLD1—uterine cancer	3.37e-05	0.000746	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	3.36e-05	0.000744	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—AKT1—uterine cancer	3.36e-05	0.000742	CbGpPWpGaD
Mefloquine—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	3.33e-05	0.000736	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—KRAS—uterine cancer	3.32e-05	0.000734	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	3.32e-05	0.000734	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—FBXW7—uterine cancer	3.29e-05	0.000728	CbGpPWpGaD
Mefloquine—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	3.28e-05	0.000726	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	3.26e-05	0.00072	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—AKR1C1—uterine cancer	3.25e-05	0.000719	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	3.24e-05	0.000717	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—AKR1C1—uterine cancer	3.16e-05	0.000698	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—RRM2—uterine cancer	3.15e-05	0.000697	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—PIK3CA—uterine cancer	3.11e-05	0.000689	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—DCN—uterine cancer	3.06e-05	0.000677	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—PIK3CA—uterine cancer	3.05e-05	0.000675	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—AKT1—uterine cancer	3.05e-05	0.000674	CbGpPWpGaD
Mefloquine—ACHE—Transmission across Chemical Synapses—HRAS—uterine cancer	3e-05	0.000664	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NDUFB11—uterine cancer	2.9e-05	0.000642	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SRD5A2—uterine cancer	2.9e-05	0.000642	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—RRM2—uterine cancer	2.9e-05	0.000641	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CYP11A1—uterine cancer	2.88e-05	0.000638	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—STK11—uterine cancer	2.88e-05	0.000636	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CCL2—uterine cancer	2.86e-05	0.000633	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—AKR1C3—uterine cancer	2.85e-05	0.000631	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—HRAS—uterine cancer	2.82e-05	0.000624	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—DCN—uterine cancer	2.81e-05	0.000622	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—RRM2—uterine cancer	2.81e-05	0.000622	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	2.8e-05	0.000619	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PGR—uterine cancer	2.78e-05	0.000615	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	2.75e-05	0.000608	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NDUFB11—uterine cancer	2.73e-05	0.000605	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SRD5A2—uterine cancer	2.73e-05	0.000605	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—DCN—uterine cancer	2.73e-05	0.000604	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—AKR1C3—uterine cancer	2.72e-05	0.000602	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SOCS3—uterine cancer	2.69e-05	0.000596	CbGpPWpGaD
Mefloquine—BCHE—Transmission across Chemical Synapses—HRAS—uterine cancer	2.68e-05	0.000592	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—YWHAE—uterine cancer	2.65e-05	0.000586	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CYP11A1—uterine cancer	2.65e-05	0.000586	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CDKN2B—uterine cancer	2.58e-05	0.00057	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CYP11A1—uterine cancer	2.57e-05	0.000569	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—AKT1—uterine cancer	2.54e-05	0.000563	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—FBXW7—uterine cancer	2.54e-05	0.000562	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IGF1R—uterine cancer	2.5e-05	0.000554	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—AKR1C3—uterine cancer	2.5e-05	0.000554	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—CXCL8—uterine cancer	2.49e-05	0.000551	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—AKT1—uterine cancer	2.49e-05	0.000551	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	2.43e-05	0.000538	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—AKR1C3—uterine cancer	2.43e-05	0.000537	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—CCL2—uterine cancer	2.42e-05	0.000535	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SMAD3—uterine cancer	2.35e-05	0.000521	CbGpPWpGaD
Mefloquine—ACHE—Neuronal System—HRAS—uterine cancer	2.3e-05	0.000508	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CXCL8—uterine cancer	2.26e-05	0.000501	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	2.25e-05	0.000499	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—FGFR2—uterine cancer	2.25e-05	0.000497	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—STK11—uterine cancer	2.22e-05	0.000491	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CCL2—uterine cancer	2.21e-05	0.000489	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—CCL2—uterine cancer	2.16e-05	0.000478	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	2.13e-05	0.000471	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—STK11—uterine cancer	2.12e-05	0.000469	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CYP19A1—uterine cancer	2.12e-05	0.000469	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—STAR—uterine cancer	2.1e-05	0.000464	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—AKR1B1—uterine cancer	2.1e-05	0.000464	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SOCS3—uterine cancer	2.08e-05	0.00046	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	2.08e-05	0.000459	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—HRAS—uterine cancer	2.05e-05	0.000454	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.99e-05	0.000441	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN2B—uterine cancer	1.99e-05	0.00044	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.98e-05	0.000438	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—STAR—uterine cancer	1.98e-05	0.000437	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—AKR1B1—uterine cancer	1.98e-05	0.000437	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—STK11—uterine cancer	1.95e-05	0.000431	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IGF1R—uterine cancer	1.93e-05	0.000428	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—CXCL8—uterine cancer	1.93e-05	0.000426	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—ESR1—uterine cancer	1.92e-05	0.000425	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—CXCL8—uterine cancer	1.91e-05	0.000423	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.9e-05	0.00042	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—STK11—uterine cancer	1.89e-05	0.000419	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CYP19A1—uterine cancer	1.89e-05	0.000419	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.88e-05	0.000415	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.83e-05	0.000405	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SMAD3—uterine cancer	1.82e-05	0.000402	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—NRAS—uterine cancer	1.82e-05	0.000402	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.79e-05	0.000395	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.79e-05	0.000395	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.78e-05	0.000393	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—CTNNB1—uterine cancer	1.77e-05	0.000391	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CXCL8—uterine cancer	1.75e-05	0.000387	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.75e-05	0.000386	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—FGFR2—uterine cancer	1.73e-05	0.000384	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—CXCL8—uterine cancer	1.71e-05	0.000378	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.69e-05	0.000375	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCL2—uterine cancer	1.69e-05	0.000374	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—POLD1—uterine cancer	1.65e-05	0.000364	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—MTHFR—uterine cancer	1.59e-05	0.000353	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.59e-05	0.000353	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—PIK3CA—uterine cancer	1.58e-05	0.00035	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—CTNNB1—uterine cancer	1.58e-05	0.000348	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—KRAS—uterine cancer	1.56e-05	0.000346	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—POLD1—uterine cancer	1.55e-05	0.000343	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—AKR1C1—uterine cancer	1.54e-05	0.000341	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ESR1—uterine cancer	1.48e-05	0.000328	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—MTHFR—uterine cancer	1.47e-05	0.000324	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.46e-05	0.000324	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—AKR1C1—uterine cancer	1.45e-05	0.000321	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—PIK3CA—uterine cancer	1.44e-05	0.000318	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—MTHFR—uterine cancer	1.42e-05	0.000315	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.42e-05	0.000313	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—ERBB2—uterine cancer	1.41e-05	0.000312	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.41e-05	0.000311	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—NRAS—uterine cancer	1.4e-05	0.00031	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—RRM2—uterine cancer	1.37e-05	0.000304	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CXCL8—uterine cancer	1.34e-05	0.000296	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—DCN—uterine cancer	1.33e-05	0.000295	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—HRAS—uterine cancer	1.33e-05	0.000294	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCL2—uterine cancer	1.31e-05	0.000289	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CDKN1B—uterine cancer	1.31e-05	0.000289	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—RRM2—uterine cancer	1.29e-05	0.000286	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—STAR—uterine cancer	1.29e-05	0.000286	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.29e-05	0.000286	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—AKT1—uterine cancer	1.29e-05	0.000286	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.29e-05	0.000286	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—DCN—uterine cancer	1.26e-05	0.000278	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP11A1—uterine cancer	1.26e-05	0.000278	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.25e-05	0.000277	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CTNNB1—uterine cancer	1.23e-05	0.000273	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—PIK3CA—uterine cancer	1.22e-05	0.00027	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—KRAS—uterine cancer	1.21e-05	0.000267	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PTEN—uterine cancer	1.2e-05	0.000266	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.2e-05	0.000265	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—AKR1C3—uterine cancer	1.19e-05	0.000262	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP11A1—uterine cancer	1.18e-05	0.000262	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—AKT1—uterine cancer	1.17e-05	0.00026	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EP300—uterine cancer	1.15e-05	0.000254	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—AKR1C3—uterine cancer	1.12e-05	0.000247	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PIK3CA—uterine cancer	1.11e-05	0.000245	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ERBB2—uterine cancer	1.09e-05	0.000241	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—VEGFA—uterine cancer	1.09e-05	0.00024	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NRAS—uterine cancer	1.07e-05	0.000237	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CXCL8—uterine cancer	1.03e-05	0.000228	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—HRAS—uterine cancer	1.03e-05	0.000227	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—POLD1—uterine cancer	1.01e-05	0.000224	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN1B—uterine cancer	1.01e-05	0.000223	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—AKT1—uterine cancer	9.98e-06	0.000221	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CTNNB1—uterine cancer	9.53e-06	0.000211	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AKR1C1—uterine cancer	9.49e-06	0.00021	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PTEN—uterine cancer	9.29e-06	0.000205	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—STK11—uterine cancer	9.24e-06	0.000204	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP19A1—uterine cancer	9.24e-06	0.000204	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KRAS—uterine cancer	9.24e-06	0.000204	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—AKT1—uterine cancer	9.06e-06	0.0002	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTEN—uterine cancer	8.87e-06	0.000196	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EP300—uterine cancer	8.86e-06	0.000196	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—STK11—uterine cancer	8.7e-06	0.000192	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP19A1—uterine cancer	8.7e-06	0.000192	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3CA—uterine cancer	8.48e-06	0.000188	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—EP300—uterine cancer	8.46e-06	0.000187	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—RRM2—uterine cancer	8.46e-06	0.000187	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—VEGFA—uterine cancer	8.39e-06	0.000186	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NRAS—uterine cancer	8.28e-06	0.000183	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—DCN—uterine cancer	8.21e-06	0.000182	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—uterine cancer	8.21e-06	0.000182	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTEN—uterine cancer	8.15e-06	0.00018	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTEN—uterine cancer	7.91e-06	0.000175	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—HRAS—uterine cancer	7.85e-06	0.000174	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—EP300—uterine cancer	7.77e-06	0.000172	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP11A1—uterine cancer	7.73e-06	0.000171	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—EP300—uterine cancer	7.55e-06	0.000167	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AKR1C3—uterine cancer	7.3e-06	0.000162	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KRAS—uterine cancer	7.13e-06	0.000158	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—MTHFR—uterine cancer	6.94e-06	0.000154	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—AKT1—uterine cancer	6.93e-06	0.000153	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CA—uterine cancer	6.55e-06	0.000145	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—MTHFR—uterine cancer	6.54e-06	0.000145	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—uterine cancer	6.34e-06	0.00014	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CA—uterine cancer	6.26e-06	0.000138	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—HRAS—uterine cancer	6.06e-06	0.000134	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CA—uterine cancer	5.75e-06	0.000127	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—STK11—uterine cancer	5.69e-06	0.000126	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP19A1—uterine cancer	5.69e-06	0.000126	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CA—uterine cancer	5.58e-06	0.000123	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—AKT1—uterine cancer	5.35e-06	0.000118	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—AKT1—uterine cancer	5.11e-06	0.000113	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—AKT1—uterine cancer	4.7e-06	0.000104	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—AKT1—uterine cancer	4.56e-06	0.000101	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MTHFR—uterine cancer	4.28e-06	9.46e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTEN—uterine cancer	3.86e-06	8.54e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—EP300—uterine cancer	3.68e-06	8.14e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTEN—uterine cancer	3.64e-06	8.05e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—EP300—uterine cancer	3.47e-06	7.67e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CA—uterine cancer	2.72e-06	6.02e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CA—uterine cancer	2.57e-06	5.68e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTEN—uterine cancer	2.38e-06	5.26e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—EP300—uterine cancer	2.27e-06	5.02e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—AKT1—uterine cancer	2.23e-06	4.92e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—AKT1—uterine cancer	2.1e-06	4.64e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.68e-06	3.71e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AKT1—uterine cancer	1.37e-06	3.03e-05	CbGpPWpGaD
